Celgene Corporation

Celgene Corporation products

A

• Abraxane® — paclitaxel protein-bound particles for injectable suspension

  • Indication: various solid tumors (e.g., breast, pancreatic, lung cancers)

I

• Idhifa® — enasidenib

  • Indication: relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation

• Imnovid® — pomalidomide (also known as Pomalyst®)

  • Indication: multiple myeloma after at least two prior therapies

• Istodax® — romidepsin

  • Indication: cutaneous and peripheral T‑cell lymphoma

• Otezla® — apremilast (sold to Amgen during BMS acquisition)

  • Indication: psoriasis and psoriatic arthritis

P

• Pomalyst® — pomalidomide (duplicate of Imnovid marketed under different names)

R

• Revlimid® — lenalidomide

  • Indications: multiple myeloma (with dexamethasone), 5q‑deleted myelodysplastic syndromes (MDS)

• Reblozyl® — luspatercept‑aamt

  • Indication: anemia in beta-thalassemia or MDS

• Revlimid duplicate; see above.

T

• Thalomid® — thalidomide

  • Indications: erythema nodosum leprosum (ENL), and, in combination with dexamethasone, multiple myeloma

V

• Vidaza® — azacitidine

• Indication: MDS and certain leukemias